Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States

References

• National Institute of Neurological Disorders and Stroke. How many people have MS? 2012; http://www.ninds.nih.gov/disorders/multiple_sclerosis/detail_multiple_sclerosis.htm#193373215. Accessed February 17, 2012
   Google Scholar
• Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-25
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Garmany GP Jr., et al. Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American academy of neurology and the MS council for clinical practice guidelines. Neurology 2002;58:169-78
   PubMed Web of Science ®Google Scholar
• Munschauer FE, Kinkel RP. Managing side effects of interferon beta in patients with relapsing–remitting multiple sclerosis. Clin Ther 1997;19:883-93
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
   Google Scholar
• Prosser LA, Kuntz KM, Bar-Or A, et al. Cost-effectiveness of interferon beta-la, interferon beta-lb, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 2004;7:554-68
   PubMed Web of Science ®Google Scholar
• Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness off our immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007;13:245-61
   PubMed Web of Science ®Google Scholar
• Earnshaw SR, Graham J, Oleen-Burkey M, et al. Cost effectiveness of glatiramer acetate and natalizumab in relapsing–remitting multiple sclerosis. Appl Health Econ Health Policy 2009;7:91-108
   PubMedGoogle Scholar
• Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci 1987;14:255-61
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112:1419-28
   PubMed Web of Science ®Google Scholar
• Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol 1989;46:1107-12
   PubMedGoogle Scholar
• Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-34
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997;49:358-63
   PubMed Web of Science ®Google Scholar
• Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• Fay AJ, Mowry EM, Strober J, et al. Relapse severity and recovery in early pediatric multiple sclerosis. Mult Scler Epub ahead of print 19 Dec 2011
   Google Scholar
• Naldi P, Collimedaglia L, Vecchio D, et al. Predictors of attack severity and duration in multiple sclerosis: a prospective study. Open Neurol J 2011;5:75-82
   PubMedGoogle Scholar
• Phadke JG. Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in northeast Scotland. J Neurol Neurosurg Psychiatry 1998;50:523-31
   Google Scholar
• United States Census Bureau. The 2012 Statistical Abstract [online]. 2012; http://www.census.gov/compendia/statab/cats/births_deaths_marriages_divorces.html. Accessed January 22, 2012
   Google Scholar
• Prosser LA, Kuntz KM, Bar-Or A, et al. Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler 2003;9:311-9
   PubMedGoogle Scholar
• Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross sectional study in the United States. Neurology 2006;66:1696-702
   PubMed Web of Science ®Google Scholar
• Medicaid Totals Q3 2011. Microsoft Office Excel 2003 [Computer Software], Microsoft Corporation. 2011; http://ahca.myflorida.com/medicaid/Prescribed_Drug/xls/111025_2011Q3_totals_Rpt.xls. Accessed February 17, 2012
   Google Scholar
• American Medical Association. CPT Code/Relative Value Search. AMA Coding [online]. https://catalog.ama-assn.org/Catalog/cpt/cpt_search.jsp?_requestid=78299. Accessed January 22, 2012
   Google Scholar
• Oleen-Burkey M, Kobelt G, Borgstrom F. Costs and quality of life of patients with relapsing-remitting multiple sclerosis currently on immunomodulatory therapy in the United States. International Committee on Databases in Multiple Sclerosis, 2003; Abstract Hackensack, New Jersey, USA
   Google Scholar
• Schmidt K, Stegman M. DRG expert: a comprehensive guidebook to the DRG classification system. 26th ed. Ingenix, 2010; Salt Lake City, Utah, USA
   Google Scholar
• Coleman CI, Roberts MS, Sidovar M. Mobility, indirect costs, and health-related quality of life in multiple sclerosis. Value Health 2012; Abstract. [In Press]
   Google Scholar
• Bureau of Labor Statistics. Consumer Price Index. United States Department of Labor [online]. http://www.bls.gov/cpi/. Accessed February 17, 2011
   Google Scholar
• AARP Public Policy Institute. Rx watchdog report: brand name drug prices continue to climb despite low general inflation rate 2010; [online]. http://assets.aarp.org/rgcenter/ppi/health-care/i43-watchdog.pdf. Accessed February 21, 2011
   Google Scholar
• CRD and CHE Technology Assessment Group. Fingolimod for the treatment of relapsing remitting multiple sclerosis. Centre for Reviews and Dissemination/Centre for Health Economics, 2011; York, UK
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Fingolimod for the treatment of relapsing-remitting multiple sclerosis in adults. 2011; http://www.nice.org.uk/nicemedia/live/12170/55812/55812.pdf. Accessed February 17, 2011
   Google Scholar
• Whetten-Goldstein K, Sloan F, Goldstein L, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-25
   PubMed Web of Science ®Google Scholar
• Greenberg D, Winkelmayer WC, Neumann PJ. Prevailing judgments about society's willingness to pay for a QALY: do they vary by country? Have they changed over time? Value Health 2006;9:A-60. Abstract
   Google Scholar
• Smyth KA. Cost-effectiveness analyses of treatments for multiple sclerosis: are they clinically relevant? Neurology 2011;77:317-8
   PubMedGoogle Scholar
• Drug Topics Staff. 2010 Top 200 branded drugs by retail dollars. Drug Topics 2011 [online]. http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252011/727252/article.pdf. Accessed February 17, 2011
   Google Scholar
• Smith B, Carson S, Fu R, et al. Drug class review: disease-modifying drugs for multiple sclerosis. Final Update 1 Report. Oregon Health and Science University, 2010; Portland, Oregon, USA. http://derp.ohsu.edu/about/final-products.cfm. Accessed February 29, 2012
   Google Scholar
• O'Day K, Meyer K, Miller RM, et al. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ 2011;14:617-27
   PubMedGoogle Scholar
• Goodin DS, Cohen BA, O'Connor P, et al. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2008;71:766-73
   PubMed Web of Science ®Google Scholar